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Abstract Gonadotropin-releasing hormone (GnRH),
which is a well-known regulator of gonadotroph func-
tion, has recently been considered to be a paracrine fac-
tor involved in the control of somatotroph, lactotroph,
and corticotroph cells. GnRH action is initiated by bind-
ing to a specific cell surface receptor, the gonadotropin-
releasing hormone receptor (GnRHR), which is ex-
pressed by follicle-stimulating hormone/luteinizing hor-
mone (FSH/LH) cells. Using in situ hybridization tech-
niques, GnRHR messenger ribonucleic acid (mRNA) has
recently been detected in normal human anterior pituita-
ry gland and in various pituitary adenomas, including
FSH/LH-cell, growth hormone (GH)-cell, adrenocortico-
tropic hormone (ACTH)-cell, and null-cell adenomas.
However, immunohistochemical studies indicating the
specific cell distribution of GnRHR in normal pituitary
cells have never been reported. The aim of the present
investigation was to evaluate the immunohistochemical
expression of GnRHR in different types of normal pitui-
tary cells and related tumors. Using double-label immu-
nohistochemical techniques on formalin-fixed and paraf-
fin-embedded tissues and specific antibodies directed
against pituitary hormones and GnRHR, we found
GnRHR immunoreactivity not only in FSH/LH cells, but
also in GH- and thyroid-stimulating hormone (TSH)
cells. GnRHR was detected in FSH/LH-cell, GH-cell,
mixed GH- and prolactin (PRL)-cell, and α-subunit 
(α-SU)/null-cell adenomas. The findings of this study
suggest that the interaction between GnRH and GnRHR
may play a role in paracrine/autocrine regulation of dif-
ferent types of normal pituitary cells and pituitary adeno-
mas.
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Introduction
The anterior pituitary gland regulates the functions of
several peripheral glands through the secretion of anteri-
or pituitary hormones. It is well known that its secretory
activity is controlled by several hypothalamic-releasing
hormones (HRHs), each of them modulating the secre-
tion of one adenohypophysial hormone. However, this
traditional view of univocal regulation of pituitary hor-
mone secretion by its specific HRH has been revisited in
the last 10 years. In fact, recent studies [17, 30, 31] have
proven that different functional cell types of the anterior
pituitary can respond to a single HRH, and pituitary cells
of the same functional type can respond to two or more
HRHs. Thyrotropin-releasing hormone (TRH), in addi-
tion to regulating thyroid-stimulating hormone (TSH) re-
lease, is a potent releaser of prolactin (PRL) [15] and,
under some circumstances, of luteinizing hormone (LH)
[9] and growth hormone (GH) [12, 32]. Other studies
have suggested that gonadotropin-releasing hormone
(GnRH), in addition to its actions on gonadotroph func-
tions, might directly interfere with GH secretion [8, 16,
22, 34].
Traditionally, GnRH has been considered to be a hy-
pothalamic hypophysiotropic-releasing hormone that
physiologically regulates the secretion of follicle-stimu-
lating hormone (FSH)/LH cell. However, GnRH messen-
ger ribonucleic acid (mRNA) has been identified in nor-
mal human adenohypophysial cells, and this finding has
suggested that GnRH, produced in the pituitary gland,
may be involved in regulation of pituitary activity
through a paracrine and/or autocrine mechanism [24, 25,
26]. The activity of GnRH depends on its binding to spe-
cific receptors (GnRHRs), which are known to be ex-
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pressed by FSH/LH-secreting cells. Although GnRHR
mRNA has recently been identified in normal pituitaries
using reverse-transcription polymerase chain reaction
(RT-PCR) and in situ hybridization (ISH) techniques [24,
26], the distribution of GnRHR in specific cell types of
normal adenohypophysis has never been evaluated.
Thus, it is unknown whether this receptor is expressed
only by FSH/LH cells or also by other functional types
of anterior pituitary cells. The hypothesis that cells, other
than FSH/LH cells, may express GnRHRs is indirectly
suggested by recent findings demonstrating GnRHR
mRNA expression in non-gonadotroph pituitary adeno-
mas, including GH-cell, adrenocorticotropic hormone
(ACTH)-cell, and null-cell adenomas [26].
Immunohistochemistry, particularly double-label tech-
niques, is useful in demonstrating the presence of two or
more antigens within the same cell. The introduction of
microwave oven heating in the double-immunostaining
technique has eliminated major drawbacks related to an-
tibody cross-reactivity and has provided several advanta-
ges over traditional methods [20]. Furthermore, the mul-
tiple immunoenzyme-staining technique has been suc-
cessfully employed in studies demonstrating colocaliza-
tion of hormones, growth factors, and growth factor re-
ceptors in normal endocrine cells and related tumors [18,
19]. This study was designed to evaluate the expression
of GnRHRs in different types of normal pituitary cells
and in pituitary adenomas using immunohistochemical
techniques and to verify whether GnRHRs are expressed
in non-gonadotrophic cells.
Materials and methods
We studied five normal pituitary glands obtained at autopsy within
24 h of death from adult subjects without endocrinological abnor-
malities and 50 well-characterized pituitary adenomas of different
types, including 12 FSH/LH-cell, 10 α-SU/null-cell, 10 GH-cell, 3
mixed GH–PRL-cell, 5 PRL-cell, 2 TSH-cell, and 8 ACTH-cell
adenomas. Tissue specimens of the pituitary adenomas were ob-
tained during transphenoidal surgery.
Tissues were fixed in buffered formalin (formaldehyde 4% w/v
and acetate buffer 0.005 mol/l) and embedded in paraffin. Sections
were stained with hematoxylin and eosin, Grimelius’ silver im-
pregnation, and alcian blue (1%, pH 2.5)–periodic acid-Schiff
(AB-PAS) technique. For immunohistochemical stains, 3-µm-thick
sections were mounted on poly-L-lysine slides and then deparaf-
finized and hydrated through a graded alcohol series, ending with
water. Endogenous peroxidase activity was inhibited by treating
sections with 3% hydrogen peroxide for 10 min. Primary antibody
incubations (Table 1) were done at 4°C for 18–20 h, followed by
the avidin-biotin peroxidase complex (ABC) procedure. Sections
were then immersed in 0.03% 3,3’-diaminobenzidine tetrahydro-
chloride and successively counterstained with Harris’ hematoxy-
lin. Colocalization studies were performed using double-label im-
munostains according to Mason [22] and Lan [20].
The anti-GnRHR antibody (clone A9E4), employed in this
study, was directed against the 1–29 NH2 terminal sequence of the
extracellular domain of the human gonadotropin-releasing hor-
mone receptor (GnRHR). Sections stained for ACTH were pre-
treated (10 min) with 0.003% subtilisin (Sigma, P4789; protease
type XXVII or Nagarse protease) in 0.05 M tris-buffered saline
pH 7.4. Sections stained with anti-FSH antibody were pretreated
by immersion into 0.01 M citrate buffer solution, pH 6, and boiled
in a microwave oven at 650 W (10 min). GnRHR antigen retrieval
was performed using a microwave oven with a pressure cooker. In
detail, slides were immersed in a plastic Coplin jar filled with 
200 ml citrate buffer (0.01 M), pH 6, and put into a pressure cook-
er containing 500 ml distilled water. The pressure cooker was
placed into the microwave that was set at 800 W for 15 min to
achieve boiling, followed by 400 W for another 15 min to main-
tain boiling. Specificity controls consisted of absorption of each
antiserum with 10–20 nM of its homologous antigen per milliliter
of diluted antiserum, omission of the first layer, and use of control
tissues with or without the pertinent antigen. The specificity of the
1–29 NH2 terminal region of GnRHR was checked using the basic
local alignment search tool (BLAST) at the National Center for
Biotechnology Information (NCBI), National Library of Medicine
(http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST/nph-newblast). The
BLAST protein database search program indicated that the amino
acid sequence 1–29 of human GnRHR does not show any structur-
al homology with other human pituitary hormones and pituitary
hormone receptors. On the contrary, a structural homology exists
between human GnRHR and GnRHRs of other species, including
pig, rat, horse, and sheep.
Results
Normal pituitary
An intense immunoreactivity (IR) for GnRHR was found
in numerous glandular cells (about 40%) of the normal
anterior pituitary. GnRHR IR was not observed in the
neurohypophysial, connective tissue, and endothelial
cells. Positive cells showed a diffuse cytoplasmic stain-
ing with reinforcement at the membrane level in some
cells. Colocalization studies (Fig. 1) demonstrated that
GnRHR was present in the cytoplasm of all α-SU-, β-
FSH-, β-LH-, and β-TSH-IR cells and of about 70% GH-
IR cells. On the contrary, PRL-IR, ACTH-IR, and S100-
IR cells did not show IR for GnRHR.
Table 1 Antibodies employed.
ACTH adrenocorticotropic hor-
mone; β-FSH β-follicle-stimulat-
ing hormone; GH growth hor-
mone; α-SU α-subunit; β-LH β-
luteinizing hormone; PRL pro-
lactin; β-TSH β-thyroid-stimu-
lating hormone; GnRHR gonado-
tropin-releasing hormone recep-
tor; P/M polyclonal/monoclonal
Antibodies P/M(clone) Tissue treatment* Dilution Source
ACTH P Subtilisin Undiluted Dako, Copenhagen, Denmark
β-FSH M(C10) Microwave 1:20 Dako
GH M(54/92A2) No 1:100 Biogenex, San Ramon, Calif.
α-SU M(5E8) No 1:5000 Prof. Ghielmi, University
of Brescia
β-LH M(3LH5B6YH4) No 1:100 Biogenex
PRL M(MIPO203) No Undiluted Biomeda, Foster City, Calif.
β-TSH M(T-790–02) No Undiluted Biomeda
protein S100 P Subtilisin 1:500 Dako
GnRHR M(A9E4) Pressure cooker 1:20 Novocastra, Newcastle, UK*See materials and methods for
details
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Fig. 1 Double-label immunostainings demonstrating that the gona-
dotropin-releasing hormone receptor (GnRHR; brown) is not ex-
pressed by prolactin (A) and adrenocorticotropic hormone (ACTH;
B) cells, but is present in growth hormone (GH; C), luteinizing hor-
mone (LH; D), and thyroid-stimulating hormone (TSH; E) cells.
All hormones are stained in red. A ×200; B–E ×400
Fig. 2 Gonadotropin-releasing hormone receptor (GnRHR) im-
munoreactivity in a follicle-stimulating hormone-luteinizing hor-
mone (FSH-LH) cell adenoma. ×200
Fig. 3 Gonadotropin-releasing hormone receptor (GnRHR)-im-
munoreactivity in a growth hormone (GH)-cell adenoma. ×200
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Pituitary adenomas
The main clinico-pathological features of the 50 pituitary
adenomas are reported in Table 2. All tumors were tested
with the anti-GnRHR antibody, and an IR was found in
the majority of FSH/LH-cell (7 of 12; Fig. 2), α-SU/null-
cell (6 of 10), GH-cell (8 of 10; Fig. 3), and mixed GH-
PRL-cell (2 of 3) adenomas. Among the GnRHR-posi-
tive adenomas, FSH/LH-cell adenomas showed the high-
est mean percentage of reactive cells. No GnRHR IR
was found in TSH-cell, ACTH-cell, and PRL-cell adeno-
mas. The IR for GnRHR did not correlate with gender
and age of patients.
Discussion
The immunohistochemical localization of GnRH binding
sites in rat pituitary cells with LH-, FSH-, and GH-IR
has been reported by Childs et al. [3] and Childs and
Unabia [2]. The localization of GnRHR in the human pi-
tuitary gland has not yet been investigated extensively.
The results of the present study clearly show, for the first
time, the presence of immunoreactive GnRHR cells in
normal human pituitary glands and in pituitary adenomas.
The IR for GnRHR in normal pituitary cells and for
pituitary adenomas was cytoplasmic, with reinforcement
at the membrane level in some cells. The membrane lo-
calization of GnRHR is in agreement with data reported
by Childs et al. [4]. The cytoplasmic GnRHR-IR may re-
present either neosynthesized or internalized receptors,
as suggested previously for other types of receptors, such
as somatostatin 2A receptors (sst2A) in specific rat brain
neurons with high somatostatin expression [7] and for
GH receptors in the human anterior pituitary gland [23].
In this context, it is interesting to recall that GnRHR, af-
ter binding with its ligand, is internalized in the cyto-
plasm [5]. This process has been well demonstrated by
Hazum et al. [13, 14], who studied pituitary gonado-
trophs and ovarian granulosa cells using immunohisto-
chemical techniques. In addition, Szende et al. [28], us-
ing electron microscopic immunohistochemical tech-
niques, have demonstrated that GnRHR was localized in
the cytoplasm and nucleus of cells of experimental pan-
creatic carcinomas of female Syrian Golden hamsters
and MXT mouse mammary cancer cells.
In the normal adenohypophysis, GnRHR was immuno-
histochemically colocalized with α-SU, β-FSH, β-LH, β-
TSH, and GH, suggesting that GnRHR is present in gonad-
otroph, thyrotroph, and somatotroph cells. The finding of
GnRHR in gonadotroph cells represents an expected result,
since it is well known that GnRH increases the synthesis
and release of gonadotropins after binding to specific cell
receptors, leading to activation of a specific G protein [6].
The finding of GnRHR expression in GH- and TSH-
cells is rather unexpected and more difficult to be ex-
Table 2 Clinico-pathological profile of 50 pituitary adenomas.
GnRHR gonadotropin-releasing hormone receptor; n number of
positive tumors; ACTH adrenocorticotropic hormone; FSH folli-
cle-stimulating hormone; GH growth hormone; α-SU α-subunit;
LH luteinizing hormone; PRL prolactin; TSH thyroid-stimulating
hormone; MP mean percentage of positive cells in reactive tumors
Adenomas Gender Age Specific GnRHR
Male/female symptoms
Mean Range n (%) MP
FSH/LH-cell 6/6 58.4 18–70 0/12 7/12 (58.3) 75.5
α-SU/null-cell 6/4 53.7 16–71 0/10 6/10 (60) 55
GH-cell 2/8 41 26–53 10/10 8/10 (80) 51.2
GH/PRL-cell 2/1 57.3 52–66 3/3 2/3 (66.6) 45
TSH-cell 2/0 40 12–68 0/2 0/2
ACTH-cell 2/6 45.5 29–58 5/8 0/8
PRL-cell 0/5 31.2 22–36 5/5 0/5
Table 3 Gonadotropin-releasing hormone receptor (GnRHR)-pro-
tein and GnRHR-messenger ribonucleic acid (mRNA) expression
in pituitary adenomas of different series. IHC immunohistochem-
istry; RT-PCR reverse transcription polymerase chain reaction;
ISH in situ hybridization; FSH/LH follicle-stimulating hor-
mone/luteinizing hormone; α-SU α-subunit; ACTH adrenocortico-
tropic hormone; PRL prolactin; GH growth hormone; TSH thy-
roid-stimulating hormone
Adenomas GnRHR protein* GnRHR mRNAa GnRHR mRNAb GnRHR mRNAc
IHC RT-PCR RT-PCR
RT-PCR ISH IS-RT-PCR
FSH/LH-cell 7/12 (58.3%) 8/10 (80%) 5/5 (100%) 3/9 (33.3%) 9/9 (100%) 4/13 (30.7%)
α-SU/null cell 6/10 (60%) 6/6 (100%) 4/12 (33.3%) 10/12 (83.3%)
ACTH-cell 0/8 1/2 (50%) 1/3 (33.3%) 2/3 (66.6%)
PRL-cell 0/5 0/2 0/4 0/4
GH-cell 8/10 (80%) 1/2 (50%) 1/5 (20%) 4/5 (80%)
GH/PRL-cell 2/3 (66.6%)
TSH-cell 0/2
*Present study; a Miller et al. 1996 [24]; b Sanno et al. 1997 [26]; c Alexander et al. 1994 [1]
plained in a physiological background. In this context, it
is worth noting that Child et al. [4] reported that, in the
rat anterior pituitary, about 38% of GH-IR cells bind bio-
tinylated GnRH. This demonstrates that at least a sub-
population of somatotrophs bears GnRH receptors. This
subpopulation of rat somatotrophs may represent precur-
sors of some somatogonadotroph cells, and the transition
between these cell types, seen from diestrus to proestrus,
may be stimulated by activin. Therefore, in rat, the ex-
pression of GnRHR by somatotrophs seems to be con-
nected with the transition from somatotrophs to somato-
gonadotrophs [2]. A similar transition is not reported in
human anterior pituitary cells, where normal somato-
troph cells are known to co-express GH and the α-SU,
but do not co-secrete GH and the β-SU [29]. In human
GH cells, GnRHR may be involved in the mechanism of
suppression of basal GH release, which may be obtained
by administration of GnRH analogues [8, 21, 34].
The possible functional role of GnRHR in thyrotrophs
is not clear at the moment, although it has been reported
that GnRH is capable of releasing significant amounts of
TSH in inhibin-treated ovine pituitary cultures [10]. Our
results, demonstrating the lack of GnRHR expression in
ACTH cells, are in agreement with the data recently pub-
lished by Wilson et al. [33], proving that GnRH agonists
do not alter the hypothalamic–pituitary–adrenal axis and
that, in particular, they do not have a suppressive effect
on the release of ACTH by the pituitary gland.
Chronic GnRH-agonist therapy has been found to re-
duce PRL level in patients with hyperprolactinemia [11].
Therefore, it may be hypothesized that the GnRH sup-
pressive effect on PRL release could be mediated by
GnRHRs present in PRL cells. However, our results
demonstrate the lack of GnRHR in PRL cells, suggesting
that the action of GnRH on PRL cells may be indirect
and possibly due to the reduction of estrogen secretion
induced by GnRH analogues.
Our results demonstrated that GnRHRs are mostly ex-
pressed by somatotroph-, gonadotroph-, and α-SU/null-cell
adenomas, while they are not expressed by PRL-cell, TSH-
cell, and ACTH-cell adenomas. This distribution of
GnRHR well reflects that found in normal pituitary cells,
with the exception of thyrotroph adenomas. Our immuno-
histochemical results concerning the distribution of
GnRHR correlate well with the expression of GnRHR
mRNA in pituitary adenomas as detected by ISH, RT-PCR,
and in situ RT-PCR (IS-RT-PCR), with the exception of
ACTH-secreting tumors [1, 24, 26] (Table 3). In fact, the
cases of functioning and nonfunctioning corticotroph ade-
nomas that we examined did not show a GnRHR IR. On
the contrary, Sanno et al. [26] demonstrated the presence of
GnRHR mRNA in a percentage of functioning cortico-
troph tumors, ranging from 33.3% to 66.6%, depending on
the technique employed. The most likely causes of these
discrepancies are differences in experimental procedures
and in the sensitivity of the methods used. The lack of
GnRHR IR in ACTH-cell adenomas may be due to the low
sensitivity of immunohistochemical methods or the low or
absent expression of receptors despite the expression of
GnRHR mRNA. In this context, it is interesting to recall
that Sanno et al. [26] detected a lower number of tumor
cells with a positive ISH signal for GnRHR in ACTH-cell
adenomas than in other types of adenomas.
Our findings, which demonstrate that tumors showing
the highest immunohistochemical expression of GnRHR
are FSH/LH- and α-SU/null-cell adenomas, are well in
agreement with those of Sanno et al. [26] who detected a
positive hybridization signal for GnRHR mRNA in the
majority of cells of FSH/LH- and null-cell adenomas ex-
amined. Interestingly, Miller et al. [24] and Sanno et al.
[26], using RT-PCR, ISH, and ISH in combination with
RT-PCR, demonstrated that GnRH and GnRHR mRNAs
are expressed in various types of human pituitary adeno-
mas, including FSH/LH-cell, GH-cell, ACTH-cell, and
null-cell adenomas. The high incidence of GnRH and
GnRHR gene expression, found in pituitary adenomas
with special reference to gonadotropin-secreting and null-
cell adenomas, suggests that locally produced hypotha-
lamic hormones and related receptors may play a role in
the regulation of tumor cell growth and function, acting
through a paracrine/autocrine mechanism. FSH/LH ade-
nomas showing diffuse IR for GnRHR (7 of 12 of our
cases) may correspond to those gonadotroph tumors that
are responsive to pulsatile GnRH in vitro and show nor-
mal tumor receptor biosynthesis [1]. On the contrary, the
FSH/LH adenomas lacking GnRHR IR (5/12 of our cases)
may correspond to the subset of gonadotroph tumors with
GnRHR biosynthetic defects and GnRH unresponsive-
ness, described by Alexander and Klibansky [1]. Whether
the heterogeneity of the immunohistochemical expression
of GnRHR among GH-cell or mixed GH-PRL-cell adeno-
mas has a functional counterpart, it remains to be verified
in combined endocrinological and pathological studies.
The lack of GnRHR-IR in our cases of PRL-cell tu-
mors perfectly correlates with results obtained by Sanno
et al. [26], who did not find GnRHR mRNA expression
in prolactinomas. These results indicate that PRL cells
do not bear GnRHRs.
The two TSH-secreting tumors examined in our series
were negative for GnRHR, and this result cannot be
compared with other cases described in the literature be-
cause, as far as we know, investigations on GnRHR or
GnRHR mRNA expression in thyrotroph adenomas are
not reported. In 1988, Simard et al. [27] demonstrated
that GnRH stimulated TSH secretion in cell cultures of a
human thyrotroph adenoma, indirectly suggesting that
adenomatous TSH cells may bear a GnRHR.
In conclusion, we demonstrated in this study that
GnRHRs are widely distributed in normal adenohypo-
physial cells and are also expressed by several pituitary
adenomas. Normal and adenomatous pituitary cells are
known to express GnRH. Therefore, it can be concluded
that the interaction between GnRH and the GnRHR may
play a role in paracrine/autocrine regulation of different
types of normal pituitary cells and pituitary adenomas.
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